Muscarinic & Novel Antipsychotics: Conference Sessions

4 sessions at 3 meetings. Xanomeline-trospium, emraclidine, TAAR1 agonists and other non-D2 antipsychotic mechanisms.

Meetings covering muscarinic & novel antipsychotics

MGH 50th Annual Psychopharmacology Conference	October 16–18, 2026	1 session →
NEI Fall Congress 2026	November 5–8, 2026	1 session →
Psych Congress 2026	September 15–19, 2026 (past)	2 sessions →

October 16–18, 2026 · Boston, MA

LectureNew Treatments for Schizophrenia
Oliver Freudenreich
Recently approved and pipeline agents for schizophrenia, including novel mechanisms.
Drug Pipeline & Clinical Trials Schizophrenia & Psychosis

November 5–8, 2026 · Colorado Springs, CO

SymposiumThe Clinical Promise of Muscarinic Agonists: Why, When, and How Across Neuropsychiatric Disorders
Stephen M. Stahl
Reviews the mechanism and clinical positioning of muscarinic agonists across neuropsychiatric conditions.
Schizophrenia & Psychosis

September 15–19, 2026 · New Orleans, LA

CourseAdvanced Psychopharmacology Intensive: Emerging Neurobiologic Targets and Metabolic Pathways Reshaping Psychiatric Treatment
Brittany Albright · Rakesh Jain · Gregory Mattingly · David Plante
Half-day ticketed intensive built around four expert-led modules on treatment mechanisms moving beyond monoamines: orexin-based agents, glutamate/dopamine circuit approaches, muscarinic receptor modulation, and GLP-1/bioenergetic pathways.
GLP-1 & Metabolic Psychiatry Neuroscience & Mechanisms Drug Pipeline & Clinical Trials
SymposiumMasterClass: Presynaptic Possibilities: The Past, Present, and Future of Modulating Dopamine
Christoph U. Correll · Chelsie Monroe
Covers presynaptic dopamine modulation in schizophrenia and bipolar I mania, including evidence for selective muscarinic agents and how to apply them to individual patients.
Bipolar Disorder Schizophrenia & Psychosis